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Background: Non-thyroidal illness (NTI) refers to changes in thyroid hormone levels in critically ill patients in the
absence of primary hypothalamic-pituitary-thyroid dysfunction, and these abnormalities usually resolve after clinical
recovery. However, NTI can be accompanied by primary thyroid dysfunction. We report herein a case of a woman
with NTI accompanied by primary hyperthyroidism.
Case presentation: A 52-year-old female was admitted to the intensive care unit with heart failure and atrial
fibrillation. She had a longstanding thyroid nodule, and a thyroid function test revealed low levels of triiodothyronine
and free thyroxine as well as undetectable thyroid stimulating hormone (TSH). She was diagnosed with NTI, and her
TSH level began to recover but not completely at discharge. The thyroid function test was repeated after 42 months to
reveal primary hyperthyroidism, and a thyroid scan confirmed a toxic nodule.
Conclusion: This case suggests that although NTI was diagnosed, primary hyperthyroidism should be considered as
another possible diagnosis if TSH is undetectable. Thyroid function tests should be repeated after clinical recovery from
acute illness.
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Non-thyroidal illness (NTI) or euthyroid sick syndrome
(ESS) is defined as a change in thyroid function during
starvation or illness including a central reduction in thy-
roid stimulating hormone (TSH) secretion, decreased
plasma triiodothyronine (T3) levels and decreased thy-
roxine (T4) and T3 binding in serum [1]. It is a relatively
common syndrome, affecting about 70% of hospitalized
patients [2] and may occur with virtually any illness [3].
Abnormalities in thyroid function can occur within
hours of acute illness, and the magnitude of reduction in
thyroid hormone levels correlates with disease severity
and mortality. Serum T3 and free T4 levels are independ-
ent predictors of survival [4-6], and low levels of T3 are
a poor prognostic factor of short- and long-term survival
in patients with heart failure, acute myocardial infarction
or acute stroke outside the intensive care unit (ICU)* Correspondence: albeppy@gmail.com
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reproduction in any medium, provided the orsetting [7,8]. The pathophysiological mechanism re-
sponsible for NTI is complex and changes in the hypo-
thalamic–pituitary–thyroid axis are the effect of various
factors. Treatment of NTI with thyroid hormone is con-
troversial, and abnormalities in thyroid function tests
usually resolve after clinical recovery [3]. Primary thy-
roid dysfunction can be accompanied by NIT, and a
follow-up thyroid function test is essential after recov-
ery from illness to ascertain normalization. Here, we
present a case of a woman with NTI who was later diag-
nosed with primary hyperthyroidism.
Case presentation
A 52-year-old woman was admitted to the cardiology
department ICU with generalized edema and orthopnea
in July 2008. She had no significant medical history and
was not taking any medications. An electrocardiogram
revealed atrial fibrillation with a heart rate of 178 beats
per minute. A chest X-ray detected pulmonary edema
and cardiomegaly. A two-dimensional echocardiogram
showed an ejection fraction of 57%, an enlarged left
atrium without thrombi and grade 3 diastolic dysfunction.
Diltiazem was used for heart rate control, but amiodarone. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Thyroid scan. 99 m-Technetium pertechnetate thyroid
scan reveals heterogeneously increased uptake in the large nodule
of the right thyroid gland with decreased uptake by the remaining
thyroid gland, suggesting a functioning nodule.
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Thyroid function tests were ordered as part of the atrial
fibrillation evaluation. Serum free T4 level was 0.282 ng/
dL (normal, 0.8–1.71 ng/dL), T3 was 0.307 ng/mL (nor-
mal, 0.6–1.6 ng/mL), and TSH was < 0.005 μIU/mL (nor-
mal, 0.4–4.8 μIU/mL). A physical examination revealed no
apparent thyroid associated orbitopathy, but a large asym-
metrical goiter, which was easily visible and palpable, was
observed. A thyroid ultrasonogram demonstrated a 4.6 ×
5.1 × 2.3 cm cystic dominant nodule in the lower portion
of the right thyroid lobe and atrophy of the contralateral
lobe (Figure 1). Five milliliters of serous, thin fluid was as-
pirated from the cyst. Aspiration cytopathology of the
solid portion of the nodule was consistent with adeno-
matous goiter. An endocrine consultation was sought to
evaluate the possibility of thyroid disease. She was diag-
nosed with NTI accompanying heart failure and a decision
was made not to replace thyroid hormones but to follow-
up on the thyroid function testing. Her symptoms re-
solved after 2 weeks, and she was subsequently discharged
with a calcium channel blocker, an angiotensin receptor
antagonist, a diuretic and aspirin. Thyroid function tests
demonstrated a free T4 level of 0.860 ng/dL, and a TSH
level of 0.017 μIU/mL at discharge.
The thyroid function tests were not followed up until
February 2012 (42 months) when she consulted the
endocrinology department again for follow-up of the
thyroid nodule. Her free T4 and T3 levels had increased
to 5.30 ng/dL and 4.80 ng/mL, respectively, and TSH
was < 0.005 μIU/mL. Anti-thyroid antibodies including
anti-TPO antibody, anti-thyroglobulin antibody and TSH-
binding inhibitory immunoglobulin were all negative. A
follow-up thyroid ultrasonogram revealed an increase in
the size of the previously observed nodule in the right lobe
to 6.4 × 7.8 × 3.2 cm with contralateral lobe atrophy.
A 99m-Technetium-pertechnetate thyroid scan demon-
strated heterogeneous uptake in the large nodule of the
right thyroid gland with no visibility in the remaining
gland, suggesting a functioning toxic nodule (Figure 2). She
refused an operation or radioactive iodine therapy; there-
fore, 10 mg methimazole twice per day was prescribed.
Her free T4 and T3 levels normalised (0.873 ng/dL andFigure 1 Ultrasonographic findings. Thyroid ultrasonogram demonstrate
the right thyroid lobe and atrophy of the contralateral lobe.0.941 ng/mL, respectively) 2 weeks later, and TSH was
0.009 μIU/mL.
Discussion
Our patient had symptoms and signs of heart failure
and atrial fibrillation. She had an asymmetric goiter,
her T3, free T4 and TSH levels all decreased signifi-
cantly; thus, she was diagnosed with NTI. TSH began
to increase at discharge, but none of the thyroid hor-
mone levels normalized. There was a follow-up loss of
the thyroid function tests until 42 months after dis-
charge. Testing revealed primary hyperthyroidism and
a thyroid scan confirmed a functioning toxic nodule.
Thus, primary hyperthyroidism, particularly toxic ad-
enoma, should be considered in patients with NTI who
have an undetectable level of TSH and a huge nodule
with an atrophic remaining thyroid gland.s a 4.6 × 5.1 × 2.3 cm cystic dominant nodule in the lower portion of
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hormone levels during various illnesses [1]. Decreased
total and free T3 levels with normal levels of TSH can be
observed in the acute phase of critical illness (low T3
syndrome). Circulating T4 levels transiently rise during
the acute phase of illness and normalize again when re-
covery follows quickly. However, patients who are se-
verely ill and suffering from diseases that do not allow
immediate recovery, present with reduced circulating
total and free T4 concentrations. Reverse T3 increases
due to impaired T4 conversion to T3 via peripheral deio-
dination. As the disease progresses, a dramatic fall in
total T4 and T3 occurs (low T4 syndrome) [9], and about
50% of patients with NTI have decreased TSH levels,
resulting from a reduction in thyroid releasing hormone
secretion by the hypothalamus and indicating changes in
hypothalamic–pituitary regulation [10]. Whether these
changes are adaptive physiological mechanisms to con-
serve energy or consequences of the underlying illness is
still a matter of debate [5,11]. However, treating NTI
with thyroid hormones does not appear to be necessary,
even though there is some controversy. For these rea-
sons, routine thyroid function tests are not recom-
mended in the intensive care setting unless a suspicion
for thyroid dysfunction is based on history or a clinical
evaluation. In the present case, a thyroid function test
was ordered to evaluate atrial fibrillation and goiter.
The resolution of abnormal thyroid hormone levels
after clinical recovery has been well documented. How-
ever, primary thyroid dysfunction can accompany NTI.
TSH level may provide some clues for detecting under-
lying thyroid disease. Spencer et al. [12,13] reported that
TSH can be low but detectable or high but < 20 μIU/mL
in patients with NTI. The likelihood ratio for primary
hyperthyroidism is 7.7 if TSH is undetectable, and the
likelihood ratio is 11.1 for primary hypothyroidism if
TSH > 20 μIU/mL [14]. Thus, TSH level should be con-
sidered in relation to the possibility of thyroid disease,
and follow-up studies are mandatory, particularly if the
value is not mildly abnormal. In our case, the patient
had an undetectable level of TSH, and a thyroid ultraso-
nogram revealed a large cystic dominant nodule in the
right thyroid lobe with atrophy of the opposite lobe. Al-
though she was diagnosed with NTI, primary hyperthy-
roidism due to the toxic nodule should have been
considered and a follow-up thyroid function test should
have been performed after discharge.
Various drugs used in the hospital, particularly in the
ICU, can alter thyroid function tests. Dopamine reduces
serum TSH if used for a prolonged time [15]. Dobutamine,
given in pharmacologic doses, also lowers TSH, even
though TSH levels remain within the normal limits in sub-
jects with a normal baseline TSH level [16]. Amiodarone is
another drug that can cause alterations in thyroid functiontests. Although most patients (>70%) on amiodarone re-
main euthyroid, the drug can lead to either amiodarone-
induced hypothyroidism or amiodarone-induced thyro-
toxicosis. High-dose glucocorticoids and octreotide also
transiently suppress TSH, although central hypothyroidism
does not appear to occur with these drugs [17,18]. Atten-
tion should be paid when interpreting thyroid function
tests if any of these drugs have been used. Our patient
never received any of these drugs.
A toxic nodule is a solitary, autonomously functioning
thyroid nodule. The pathogenesis includes mutations in
the TSH receptor leading to enhanced stimulation of
thyroid follicular cell proliferation and function [19]. A
thyroid nodule generally large enough to be palpable is
present with suppressed TSH level, as in the present
case. Patients initially have subclinical hyperthyroidism
but when the adenoma grows to a significant size, frank
hyperthyroidism develops, and elevated serum thyroid
hormone levels accompany this condition [20]. Thyro-
toxicosis is usually mild. A thyroid nodule appears on
ultrasonography as a hypo-echogenic nodule with an
atrophic thyroid gland. A thyroid scan is a definitive
diagnostic test, demonstrating increased radioiodine up-
take in the hyperfunctioning nodule and decreased up-
take in the remaining gland. Radio-iodine ablation is
usually the treatment of choice. Surgical resection of the
adenoma or lobectomy to preserve thyroid function is
another treatment option [1].
Conclusion
NTI is a very common syndrome in the intensive care
setting, and routine thyroid function testing is generally
not recommended. However, if there is a high suspicion
for underlying thyroid disease, a thyroid function test
should be performed and interpreted with caution. Thy-
roid function tests should be repeated after recovery
from acute illness to ascertain euthyroid status. An
evaluation for primary thyroid disease is essential, par-
ticularly when TSH is undetectable or >20 μIU/mL.
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